Skip to content

Corvus Pharma up on encouraging CPI-006 data in COVID-19

September 10, 2020

Corvus Pharmaceuticals (NASDAQ:CRVS) jumps 10% premarket after announcing updated data from its ongoing Phase 1 study investigating the potential for CPI-006 to provide a novel immunotherapy approach for patients with COVID-19.

The Company has submitted a manuscript describing the initial results from the first two cohorts (five patients receiving 0.3 mg dose and five patients receiving 1.0 mg dose) for publication online at medRxiv.org. The key highlights are as follows:

Nine of 9 patients with pre-treatment serum samples had low pre-treatment levels of anti-SARS-CoV-2 antibodies independent of the duration of their prior COVID-19 symptoms.

IgG and IgM antibody titers against the SARS-CoV-2 trimeric spike and/or receptor binding domain increased in 8 of 8 evaluable patients within seven days of receiving the treatment. In five patients measured, the antibodies were neutralizing.

In all patients evaluated, the antibody responses, including Neutralizing antibody titers continued to increase out to 28 days post treatment with CPI-006.

In three of three patients tested to-date, CD4 and CD8 T effector memory cells increased by day 28 and these cells were shown to respond specifically to SARS-CoV-2 viral antigens.

In addition, all of these patients were discharged from the hospital with clinical improvement and none experienced any drug-related safety issues.

The study has completed enrollment in the third cohort (3.0 mg dose of CPI-006) of five patients, with the overall study expected to enroll up to 30 patients.

“CPI-006’s unique immunotherapy approach to treating COVID-19 may provide advantages over other therapies in development. Specifically compared to passively administered monoclonal antibody approaches, we believe CPI-006 could trigger B cell activation at much lower antibody dose levels and provide activity against potential new mutant variants,” said Richard A. Miller, M.D., President and CEO.

Additional data are expected in late 2020.

https://seekingalpha.com/news/3612898-corvus-pharmaplus-10-on-encouraging-cpiminus-006-data-in-covidminus-19

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: